首页> 美国卫生研究院文献>Oncology Letters >Androgen deprivation therapy has no effect on Pim-1 expression in a mouse model of prostate cancer
【2h】

Androgen deprivation therapy has no effect on Pim-1 expression in a mouse model of prostate cancer

机译:雄激素剥夺疗法对前列腺癌小鼠模型中Pim-1表达没有影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of the present study was to observe the dynamic changes of proto-oncogene, serine/threonine kinase, Pim-1 at the gene and protein level in a mouse model of prostate cancer following surgical castration. Using LNCaP cells to establish a subcutaneous xenograft model and orthotopic prostate cancer BALB/c nude mouse models, the xenograft models were divided into an androgen-dependent prostate cancer group (ADPC), an androgen deprivation therapy (ADT) group and an androgen independent prostate cancer (AIPC) group. Reverse transcription-polymerase chain reaction (RT-PCR), RT-quantitative PCR, ELISA and immunohistochemistry analyses were performed to compare the expression levels of Pim-1, prostate-specific antigen (PSA) and androgen receptor (AR) in tumor tissue of three subgroups. Agarose gel electrophoresis revealed that the RT-PCR results of the ADPC (0.59±0.01) and AIPC groups (1.14±0.015) were significantly different when compared with the ADT group (0.62±0.026; P<0.05). As for RT-qPCR, the ΔCq of Pim-1 in the ADPC (6.15±0.34) and AIPC (4.56±0.23) groups were significantly different compared with the ADT group (5.11±0.21; P<0.05). Using 2−ΔΔCq as a relative quantification method to analyze the data, the amplification products of Pim-1 increased by 2.05 and 3.01 times in the ADT and AIPC groups, respectively. ELISA demonstrated the following: The serum concentration of PSA was 0 ng/ml in the control group, 0.48±0.025 ng/ml in the ADPC group and 0.87±0.023 ng/ml in the AIPC group, which were significantly different compared with the ADT group (0.17±0.032 ng/ml; P<0.01). Upon immunohistochemical staining, the protein expression levels of Pim-1 and AR, respectively, were 0.017±0.0021 and 0.032±0.009 in the ADPC group, 0.024±0.0019 and 0.040±0.011 in the AIPC group, and 0.018±0.0013 and 0.019±0.006 in the ADT group. The protein levels of Pim-1 and AR in the ADPC and AIPC groups were significantly different compared with the ADT group (P<0.01). In addition, an orthotopic prostate cancer animal model of ADT was successfully established in the current study, and further investigation revealed that ADT did not affect the expression of Pim-1 at the gene or protein levels; thus, it is hypothesized that Pim-1 may be important in the proliferation and differentiation of prostate cancer during ADT.
机译:本研究的目的是观察前列腺癌手术去势后小鼠模型中原癌基因,丝氨酸/苏氨酸激酶,Pim-1在基因和蛋白质水平的动态变化。使用LNCaP细胞建立皮下异种移植模型和原位前列腺癌BALB / c裸鼠模型,将异种移植模型分为雄激素依赖性前列腺癌组(ADPC),雄激素剥夺治疗(ADT)组和雄激素依赖性前列腺癌组癌症(AIPC)组。进行了逆转录聚合酶链反应(RT-PCR),RT定量PCR,ELISA和免疫组化分析,比较了Pim-1,前列腺特异性抗原(PSA)和雄激素受体(AR)在肿瘤组织中的表达水平。三个子组。琼脂糖凝胶电泳显示,ADPC组(0.59±0.01)和AIP​​C组(1.14±0.015)的RT-PCR结果与ADT组(0.62±0.026; P <0.05)相比有显着差异。对于RT-qPCR,ADPC组(6.15±0.34)和AIP​​C(4.56±0.23)组中Pim-1的ΔCq与ADT组(5.11±0.21; P <0.05)有显着差异。使用2 -ΔΔCq作为相对定量方法分析数据,在ADT和AIPC组中,Pim-1的扩增产物分别增加了2.05和3.01倍。 ELISA检测结果如下:对照组PSA血清浓度为0 ng / ml,ADPC组为0.48±0.025 ng / ml,AIPC组为0.87±0.023 ng / ml,与ADT相比有显着差异组(0.17±0.032ng / ml; P <0.01)。免疫组织化学染色后,ADPC组Pim-1和AR的蛋白表达水平分别为0.017±0.0021和0.032±0.009,AIPC组分别为0.024±0.0019和0.040±0.011,0.018±0.0013和0.019±0.006在ADT组中。 ADPC组和AIPC组的Pim-1和AR蛋白水平与ADT组相比有显着差异(P <0.01)。此外,本研究成功建立了原位前列腺癌ADT的原位前列腺癌动物模型,进一步的研究表明,ADT在基因或蛋白质水平上均不影响Pim-1的表达。因此,假设Pim-1可能在ADT期间对前列腺癌的增殖和分化起重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号